Skip to search formSkip to main contentSkip to account menu

SPI-1620

Known as: Endothelin B Receptor Agonist SPI-1620 
A highly selective peptide agonist of the endothelin-B receptor. Endothelin B receptor agonist SPI-1620 binds to endothelin-B receptors on… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

IRL 1620

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment
Background:This multicentre, open-label study evaluated the efficacy and safety of SPI-1620, an analogue of endothelin-1… 
2012
2012
IRL-1620, an endothelin-B receptor agonist, enhanced radiation induced reduction in tumor volume in Dalton's Lymphoma Ascites tumor model.
ETB receptor agonist, IRL-1620 (or SPI-1620) presently in US Phase 1 clinical trial, has been demonstrated to selectively and… 
2009
2009
Abstract #2333: Determination of SPI-1620 mediated blood flow increase in tumors using PET imaging
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO Aim : The ETB receptor peptide agonist, SPI-1620, has been demonstrated to… 
2007
2007
Effect of SPI-1620 on tumor perfusion and uptake of paclitaxel in a melanoma model
B3 Background: SPI-1620 (also known as IRL-1620) is a selective ETB receptor agonist that has been reported to selectively… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License